Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, January 4, 2023
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
Tue, January 3, 2023
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
[ Tue, Jan 03rd 2023
] - WOPRAI
Raghuram Selvaraju Maintained (ADMA) at Strong Buy with Increased Target to $4.5 on, Jan 3rd, 2023
Raghuram Selvaraju of HC Wainwright & Co., Maintained "ADMA Biologics, Inc." (ADMA) at Strong Buy with Increased Target from $4 to $4.5 on, Jan 3rd, 2023.
Raghuram has made no other calls on ADMA in the last 4 months.
There is 1 other peer that has a rating on ADMA. Out of the 1 peers that are also analyzing ADMA, 0 agree with Raghuram's Rating of Hold.
This is the rating of the analyst that currently disagrees with Raghuram
- Anthony Petrone of "Mizuho" Maintained at Strong Buy with Increased Target to $6 on, Thursday, November 10th, 2022
